Gastroparesis News and Research

RSS
Gastroparesis, also called delayed gastric emptying, is a disorder in which the stomach takes too long to empty its contents. Normally, the stomach contracts to move food down into the small intestine for digestion. The vagus nerve controls the movement of food from the stomach through the digestive tract. Gastroparesis occurs when the vagus nerve is damaged and the muscles of the stomach and intestines do not work normally. Food then moves slowly or stops moving through the digestive tract.
Painless magnetic stimulation dramatically reduces episodes of fecal incontinence

Painless magnetic stimulation dramatically reduces episodes of fecal incontinence

Congressional briefing on moving away from dog studies in the development of new medicines

Congressional briefing on moving away from dog studies in the development of new medicines

Researchers use MRI to watch how electrical stimulation could cure gastrointestinal disorders

Researchers use MRI to watch how electrical stimulation could cure gastrointestinal disorders

Key features that distinguish Brittle Type 1 Diabetes from stable T1D

Key features that distinguish Brittle Type 1 Diabetes from stable T1D

Study shows efficacy of antipsychotic as adjunctive therapy for gastroparesis in emergency department

Study shows efficacy of antipsychotic as adjunctive therapy for gastroparesis in emergency department

Studies show how endoscopic procedures can improve outcomes and care

Studies show how endoscopic procedures can improve outcomes and care

Novel portable wireless device can monitor stomach motility in patients suffering from gastroparesis

Novel portable wireless device can monitor stomach motility in patients suffering from gastroparesis

Johns Hopkins study shows that healthy adult gut loses and regenerates nerve cells

Johns Hopkins study shows that healthy adult gut loses and regenerates nerve cells

TTUHSC El Paso investigators receive $1.8 million grant to support digestive disorder research

TTUHSC El Paso investigators receive $1.8 million grant to support digestive disorder research

Cairn launches non-invasive Gastric Emptying Breath Test for measuring rate of gastroparesis in adults

Cairn launches non-invasive Gastric Emptying Breath Test for measuring rate of gastroparesis in adults

Rhythm Metabolic awarded FDA grant to advance ongoing setmelanotide clinical trial in Prader-Willi syndrome

Rhythm Metabolic awarded FDA grant to advance ongoing setmelanotide clinical trial in Prader-Willi syndrome

Rhythm Metabolic completes $40 million Series A financing

Rhythm Metabolic completes $40 million Series A financing

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Rhythm announces initiation of two setmelanotide Phase 2 trials for treatment of PWS, POMC-null obesity

Rhythm announces initiation of two setmelanotide Phase 2 trials for treatment of PWS, POMC-null obesity

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis provides overview of standalone global pharmaceutical development pipeline

Altos Therapeutics announces issuance of Mexican patent covering dopamine D2/D3 drug candidates

Altos Therapeutics announces issuance of Mexican patent covering dopamine D2/D3 drug candidates

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

Targacept reports net loss of $11.6M in first quarter 2014

Targacept reports net loss of $11.6M in first quarter 2014